These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1992569)

  • 21. High risk biochemical relapse and the timing of androgen deprivation therapy.
    Ryan CJ; Small EJ
    J Urol; 2006 Dec; 176(6 Pt 2):S61-5. PubMed ID: 17084171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur).
    Christensen MM; Aagaard J; Madsen PO
    Prog Clin Biol Res; 1990; 359():7-14; discussion 15-24. PubMed ID: 2284298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic approach to hormone-refractory prostate cancer.
    Saad F; Al Dejmah A; Perrotte P; McCormack M; Bénard F; Valiquette L; Karakiewicz PI
    Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
    Berthelet E; Pickles T; Lee KW; Liu M; Truong PT;
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):781-7. PubMed ID: 16199312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma.
    Jordan WP; Blackard CE; Byar DP
    South Med J; 1977 Dec; 70(12):1411-3. PubMed ID: 594790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation therapy as primary treatment for prostate cancer.
    Cannata DH; Kirschenbaum A; Levine AC
    J Clin Endocrinol Metab; 2012 Feb; 97(2):360-5. PubMed ID: 22162475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation.
    Cookson MS; Sarosdy MF
    South Med J; 1994 Jan; 87(1):1-6. PubMed ID: 8284708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormonal therapy for advanced prostatic carcinoma.
    Seftel AD; Spirnak JP; Resnick MI
    J Surg Oncol Suppl; 1989; 1():14-20. PubMed ID: 2669792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.
    Bellmunt J; Rosenberg JE; Choueiri TK
    Eur Urol; 2009 Oct; 56(4):606-8. PubMed ID: 19635642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.